Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CBS001 in healthy volunteers
NCT05323110Phase 1Terminated
- Sponsor
- Capella Bioscience Ltd.
- Start
- Apr 2022
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CBS001 in chronic inflammatory disease (2 arms), sponsored by Capella Bioscience Ltd. Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Apr 2022; status: terminated.
02
Drugs
CBS001
03
Conditions
chronic inflammatory disease
Beyond the preview
Go deeper on NCT05323110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05323110.